Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Special Drug Use Surveillance for EFIENT Tablets in High-Risk Ischemic Cerebrovascular Disease
jRCT2031220131Recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of prasugrel in Ischaemic cerebral disease and ischemic stroke, sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Incidence of bleeding events and Incidence of ischemic stroke events. Started Jul 2022; status: recruiting.
02
Drugs
prasugrel
03
Conditions
Ischaemic cerebral diseaseischemic stroke
Beyond the preview
Go deeper on jRCT2031220131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220131.